Shenzhen iCarbonX PeptideTech Pharmaceutical Technology Co., Ltd. and Hybio Pharmaceutical Co., Ltd. have inked a cooperation deal, formalizing their partnership with the "Strategic Cooperation Agreement on Innovative Drug CRDMO Services" and the "Strategic Investment Agreement." These agreements mark a collaborative effort to propel the comprehensive development of several cutting-edge drug projects, encompassing preclinical research through to commercial production. By leveraging the groundbreaking "Peptide Chip + Artificial Intelligence" technology, iCarbonX PeptideTech specializes in the innovative design and discovery of peptide drugs. Currently, the company is expediting projects such as iCPDC-001, an antimicrobial peptide initiative, and the multi-target drug HY3003.

This collaboration stands as a pivotal milestone in iCarbonX PeptideTech's "technology-driven + industrial synergy" strategy. The aim is to synergize Hybio's extensive CRDMO capabilities and global market resources to collectively drive forward the research, development, and commercialization of even more innovative drugs.